A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Futuximab/modotuximab (Primary)
- Indications Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 19 Jan 2019 Results establishing a popPK model for Sym004 using data from 4 trials (Sym004-01, Sym004-02, Sym004-05 and Sym004-06) presented at the 2019 Gastrointestinal Cancers Symposium
- 01 Oct 2018 Results published in the Cancer Science
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology